Can the new CEO at Genen­tech main­tain a tra­di­tion of ground­break­ing R&D?

Dur­ing the 6 years that Ian Clark man­aged Genen­tech as its CEO, he nev­er lost sight of the sin­gu­lar mis­sion he had at the big Roche sub­sidiary. Like Pas­cal So­ri­ot be­fore him, and now Bill An­der­son com­ing in af­ter his de­par­ture at the end of this year, job 1 at Genen­tech is keep­ing the phar­ma gi­ant’s unique­ly pro­duc­tive R&D op­er­a­tion fo­cused on big new prod­ucts.

That job pro­file hasn’t changed one bit. This is what Roche’s Daniel O’Day, CEO of Roche’s phar­ma di­vi­sion, had to say on Clark’s re­place­ment at the helm:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER